NL-OMON25046招募中不适用
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.
HOVON foundation0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients eligible for standard chemotherapy;
- •2. Patients ≥ 66 years with a cytopathologically confirmed diagnosis according WHO classification of:
排除标准
- •1. Acute promyelocytic leukemia;
- •2. Patients previously treated for AML (any antileukemic therapy including investigational agents)- a short treatment period (< 2 weeks) with Hydroxyurea is allowed;
研究者
相似试验
招募中
不适用
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged >66 years .Acute Myeloid Leukemia (AML), MDSNL-OMON25024HOVON Data Center230
已完成
不适用
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.Acute Myeloid leukemia (AML), RAEBNL-OMON22002HOVON Data Center200
招募中
不适用
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years.A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients.Acute Myeloid Leukemia (AML), MyelodysplasiaNL-OMON19923HOVON Data Center185
已完成
不适用
A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.Myelodysplastic syndrome (MDS)NL-OMON20915Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Postbus 2040; 3000 CA Rotterdam; Tel: +31 10 704 1560 Fax: +31 10 704 1028; e-mail: hdc@erasmusmc.nl200
进行中（未招募）
不适用
Stuyd for the treatment of patients with leukemic cells (cancer) in their bone marrowpatients = 66 years with:o a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, oro acute leukemia's of ambiguous lineage according to WHO 2008 oro a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R > 4.5MedDRA version: 17.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: LLTClassification code 10037803Term: RAEBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014455-68-BEHOVON Foundation240